Clinical research progress on drugs for non-alcoholic steatohepatitis treatment
10.16438/j.0513-4870.2023-1199
- VernacularTitle:非酒精性脂肪肝炎治疗药物临床研发进展
- Author:
Cai-hong LIU
1
,
2
;
Shao-cong HOU
1
,
2
;
Ping-ping LI
1
,
2
Author Information
1. State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
2. CAMS Key Laboratory of Molecular Mechanism and Target Discovery of Metabolic Disorder and Tumorigenesis, Beijing 100050, China
- Publication Type:Research Article
- Keywords:
nonalcoholic steatohepatitis;
lipid metabolism;
gut-liver axis;
anti-inflammation;
anti-fibrosis
- From:
Acta Pharmaceutica Sinica
2023;58(12):3528-3538
- CountryChina
- Language:Chinese
-
Abstract:
Nonalcoholic steatohepatitis (NASH) is the leading chronic liver disease worldwide. NASH is commonly associated with metabolic risk factors, including obesity, hypertension, and diabetes. Hepatic glucose and lipid metabolism disorder, bile acid toxicity, oxidative stress, inflammation, fibrosis, intestinal dysbacteriosis, and susceptibility gene variation are involved in the pathogenesis of NASH. Drug development for NASH has been slow, this article focuses on the clinical research and development of several promising NASH drugs and their mechanisms, such as drugs targeting gut-liver axis, improving metabolism, inhibiting inflammation and fibrosis.
